Myelodysplastic Syndromes
Showing 1 - 25 of 2,770
MDS Trial run by the National Cancer Institute (NCI) (decitabine and cedazuridine, BMS-986253)
Not yet recruiting
- Myelodysplastic Syndromes
- decitabine and cedazuridine
- BMS-986253
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Biospecimen Acquisition for Myelodysplastic Syndromes
Recruiting
- Myelodysplastic Syndromes
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
Relapsed / Refractory MDS Trial (NCR300)
Not yet recruiting
- Relapsed / Refractory Myelodysplastic Syndromes
- (no location specified)
May 7, 2022
Interplay Between Immune and Metabolic Programs in
Recruiting
- Myelodysplastic Syndromes
-
Toulouse, FranceIUCT-Oncopole University Hospital
May 17, 2022
Mean Platelet Volume and Its Relation to Risk Stratification of
Completed
- Myelodysplastic Syndromes
- (no location specified)
Jan 21, 2022
Low Risk MDS Trial (R906289 Monosodium (R289 Na))
Not yet recruiting
- Low Risk Myelodysplastic Syndromes
- R906289 Monosodium (R289 Na)
- (no location specified)
Jul 22, 2022
Acute Myeloid Leukemia, MDS Trial in Rochester (Inpatient serious illness care program)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Inpatient serious illness care program
-
Rochester, New YorkUniversity of Rochester
Jun 21, 2022
MDS, MDS Trial in Tampa, Boston, Houston (APR-548 + Azacitidine)
Terminated
- MDS
- Myelodysplastic Syndromes
- APR-548 + Azacitidine
-
Tampa, Florida
- +3 more
Jul 20, 2022
Clonal Cytopenia of Undetermined Significance, MDS Trial in Saint Louis (Atorvastatin, Rosuvastatin)
Not yet recruiting
- Clonal Cytopenia of Undetermined Significance
- Myelodysplastic Syndromes
-
Saint Louis, MissouriWashington University School of Medicine
Jul 28, 2022
MDS Trial in Saint Louis (vosaroxin, Azacitidine)
Active, not recruiting
- Myelodysplastic Syndromes
-
Saint Louis, MissouriWashington University School of Medicine
Mar 23, 2022
Leukemias, MDS Trial in Houston (sapacitabine)
Completed
- Leukemias
- Myelodysplastic Syndromes
-
Houston, TexasThe University of Texas MD Anderson Cancer Center
Dec 7, 2021
Recurrent/Refractory Acute Myeloid Leukemia, MDS Trial in ChengDu (TQB2618 injection azacitidine, AZA decitabine, DAC)
Recruiting
- Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
- TQB2618 injection azacitidine, AZA decitabine, DAC
-
ChengDu, Sichuan, ChinaWest China Hospital of Sichuan University
Jun 16, 2022
MDS Trial in New York (selinexor (KPT-330))
Completed
- Myelodysplastic Syndromes
- selinexor (KPT-330)
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 11, 2022
MDS Trial (Pevonedistat, Azacitidine)
No longer available
- Myelodysplastic Syndromes
- (no location specified)
Sep 8, 2021
MDS, Myeloproliferative Tumors, Myelofibrosis Trial (Jaktinib, azacitidine)
Not yet recruiting
- Myelodysplastic Syndromes
- +2 more
- (no location specified)
Nov 29, 2021
Lower-risk Myelodysplastic Trial in Tokyo (ASTX727)
Active, not recruiting
- Lower-risk Myelodysplastic
-
Tokyo, JapanNTT Medical Center Tokyo
Jan 14, 2022
MDS Trial in Bronx (Pyrimethamine)
Withdrawn
- Myelodysplastic Syndromes
-
Bronx, New YorkMontefiore Medical Center
Sep 15, 2021
Strategy for High-Risk Myelodysplastic Syndromes in Patients
Active, not recruiting
- Myelodysplastic Syndromes
- Allogeneic Stem Cell Transplantation
-
Agen, France
- +9 more
Jul 5, 2022
Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, MDS Trial in Cleveland (CPX-351)
Recruiting
- Refractory Acute Myeloid Leukemia
- +2 more
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Mar 15, 2022
MDS Trial (Fasting-mimicking diet (FMD) and physiotherapy)
Not yet recruiting
- Myelodysplastic Syndromes
- Fasting-mimicking diet (FMD) and physiotherapy
- (no location specified)
Jun 22, 2022
MDS, Acute Myeloid Leukemia Trial (Sabatolimab, Magrolimab, Azacitidine)
Not yet recruiting
- Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Sabatolimab
- +2 more
- (no location specified)
May 24, 2022
Physical Activity in Transfusion Dependent Myelodysplastic
Recruiting
- Myelodysplastic Syndromes
- Medical Device Usage and Evaluation
- +3 more
-
Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
Aug 16, 2022